Clostridia Consortia Reverse Colitis via Tryptophan‑Driven Microbiome and Immune Modulation

Defined human Clostridia consortia 17‑mix and 11‑mix reverse established colitis in multiple murine IBD models. Beyond SCFA and IL‑10 pathways, these live biotherapeutic products suppress resident pathobionts and activate anti‑inflammatory AhR signaling via bacterial tryptophan metabolites, revealing IL‑10‑independent mechanisms of microbiome‑based therapy.


Read full article for free (open access):

https://www.sciencedirect.com/science/article/pii/S1931312826003239


Live biotherapeutic products ease colitis by suppressing pathobionts & activating AhR anti‑inflammatory pathways independently of SCFAs & IL‑10.


Popular posts from this blog

Salivary microbiome diversity is associated with oral health and disease

Pacific has one of most successful years for grants in school history